09:39 AM EDT, 10/25/2024 (MT Newswires) -- LakeShore Biopharma ( LSB ) said Friday that it has been granted approval by China's National Medical Products Administration for a phase 3 clinical study of a simplified four-dose regimen for its YSJA rabies vaccine.

The biopharmaceutical company said the study will begin in December and will evaluate the immunogenicity and safety of its YSJA rabies vaccine across two four-dose immunization schedules compared with the existing five-dose Essen regimen.

Shares of LakeShore Biopharma ( LSB ) were down more than 4% in early trading Friday.

Price: 3.0000, Change: -0.14, Percent Change: -4.46